You are running an unsupported browser, please upgrade your browser. Close

Adenovirus (AV) Production

Pall's end-to-end process support, from development to industrialization with a set of scalable solutions for adenovirus production.

End-to-end process support, from development to industrialization

Adenoviral (AV) vectors are an efficient gene delivery system for a broad range of cell types and are one of the most commonly employed viral vectors for potential new therapies and vaccines. Much progress has been made in developing commercial production-scale processes for gene therapies and vaccines in recent decades, but challenges persist around cell associated virus and scalability due to purification recovery efficiency.  We offer a wide range of robust, scalable upstream and downstream solutions; and has the technical knowledge and experience to support each step of the entire process. Most AV vector production follows the same basic process, with some variation as needed.

 

Upstream

     

 

 

Downstream

     

White Paper:
An End-to-End Process for Large-Scale Adenovirus Manufacturing for Gene Therapy

 

Download

 

 

Poster:

Industrialization of AdenoVirus Production and Purification with the iCELLis® 500 Single-Use Bioreactor (A4 Version)

 

Download

 

Upstream

Adherent Cell Seeding

Adherent Cell Culture

Clarification

Want to learn more about 

Upstream Process 

workflows? 

Speak to an expert

 

Downstream

Bioburden Filtration

Purification (Chromatography)

UF/DF

Bulk Drug Substance Filtration

Want to learn more about 

Downstream Process 

workflows? 

Speak to an expert

 

Complementary Technologies

Connect With An Expert

 

 

 

 

Pall has a global team of over 300 experienced technical professionals to support your molecule from pre-clinical to commercial manufacturing. From process development services and end-to-end platforms, to on-site testing and applications support for specific process steps, Pall will help you find the best solution based on data and testing.